Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140439 | 0.86 | TAAR1 (0.50) | TAAR1CNR1OPRM1OPRD1OPRK1 | |
| SCHEMBL22857525 | 0.82 | TAAR1 (0.57) | TAAR1CNR1OPRM1KMT2AOPRD1 | |
| SCHEMBL1010528 | 0.77 | TAAR1 (0.62) | TAAR1CNR1OPRM1ALDH1A1HPGD | |
| SCHEMBL12930792 | 0.77 | TAAR1 (0.53) | TAAR1MEN1KMT2A | |
| SCHEMBL4142774 | 0.75 | CNR1 (0.44) | TAAR1CNR1OPRM1MEN1ALDH1A1 | |
| SCHEMBL4142778 | 0.75 | CNR1 (0.44) | TAAR1CNR1OPRM1MEN1ALDH1A1 | |
| SCHEMBL4142769 | 0.75 | CNR1 (0.44) | TAAR1CNR1OPRM1MEN1ALDH1A1 | |
| SCHEMBL5117230 | 0.72 | CNR1 (0.59) | TAAR1CNR1OPRM1ALDH1A1OPRD1 | |
| SCHEMBL4138386 | 0.72 | MMP8 (0.65) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4145237 | 0.72 | POLB (0.57) | MEN1ALDH1A1HPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | TAAR1 4308/4885CNR1 1655/4885OPRM1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.